


## Claims


1. A pharmaceutical, antimycotically active formulation for the treatment or prophylaxis of fungal infections of nails and skin, comprising an optionally substituted 2-aminothiazole of formula (I)



wherein

$R^1$  represents hydrogen or alkyl, and

$R^2$  represents a substituent of the formula



10 wherein



$R^3$ ,  $R^4$ ,  $R^5$  and  $R^6$  independently from each other represent hydrogen, halogen, nitro, alkyl, alkoxy, alkoxy-carbonyl, dialkylamino, alkylthio, alkylsulphinyl, alkylsulphonyl, halogenoalkyl, halogenoalkoxy, halogenoalkylthio, halogenoalkylsulphinyl or halogenoalkylsulphonyl,

15 X represents oxygen, sulphur, sulphinyl or sulphonyl, and

Ar represents an optionally substituted aryl moiety, and


their physiologically acceptable acid addition salts,

wherein the compounds of formula (I) are in equilibrium with the tautomeric compounds of formulae (Ia) and (Ib)



wherein  $R^1$  and  $R^2$  in each case have the abovementioned meanings.


2. A pharmaceutical, antimycotically active formulation for the treatment or prophylaxis of fungal infections of nails and skin, comprising an optionally substituted 2-aminothiazole of formula (I)



wherein

$R^1$  represents hydrogen or alkyl, and

$R^2$  represents a substituent of the formula



wherein

$R^3$ ,  $R^4$ ,  $R^5$  and  $R^6$  independently from each other represent hydrogen, halogen, nitro, alkyl, alkoxy, alkoxy-carbonyl, dialkylamino, alkylthio, alkylsulphinyl,


alkylsulphonyl, halogenoalkyl, halogenoalkoxy, halogenoalkylthio,  
halogenoalkylsulphanyl or halogenoalkylsulphonyl,

X represents oxygen, and

Ar represents an optionally substituted aryl moiety, and

5 their physiologically acceptable acid addition salts,

wherein the compounds of formula (I) are in equilibrium with the tautomeric  
compounds of formulae (Ia) and (Ib)



wherein R<sup>1</sup> and R<sup>2</sup> in each case have the abovementioned meanings.

10

3. A pharmaceutical, antimycotically active formulation according to claim 1 or 2, characterized in that it comprises a permeation enhancer.

4. A pharmaceutical, antimycotically active formulation according to claim  
15 3, wherein the permeation enhancer is hyaluronate lyase.

5. A pharmaceutical, antimycotically active formulation according to one of claims 1 to 4, characterized in that it comprises a polymeric film-forming agent.

20 6. A pharmaceutical, antimycotically active formulation according to claim 5, characterized in that the film-forming agent belongs to the group of water-insoluble acrylate polymers or methacrylate polymers and comprises a copolymer that belongs to the compound class of alkylvinylethers, maleic acid anhydride, alkylated poly(vinylpyrrolidones) and ammonium methacrylates.

25

7. A pharmaceutical, antimycotically active formulation according to one of claims 1 to 6, characterized in that it comprises a plasticizer.
8. A pharmaceutical, antimycotically active formulation according to one of  
5 claims 1 to 7, characterized in that it comprises at least one solvent.
9. A pharmaceutical, antimycotically active formulation according to claim 8, characterized in that it comprises as a solvent ethanol, ethyl acetate, butyl acetate, isopropanol, acetone, methyl ethyl ketone, triacetin, tripropionin, diethylene glycol  
10 monoethyl ether, isopropyl acetate, or a mixture of two or more of said solvents.
10. A pharmaceutical, antimycotically active formulation according to one of claims 1 to 9, comprising  
from 0.1 to 20% antimycotic agent,  
15 from 0.5 to 35% permeation enhancer,  
from 0.5 to 40% film-forming polymer,  
from 5 to 80% volatile solvent, and  
from 1.0 to 10% plasticizer.
- 20 11. A pharmaceutical, antimycotically active formulation according to one of claims 1 to 10, wherein the antimycotically active ingredient is Abafungin.
12. A method for the treatment of fungal infections, in which a pharmaceutical, antimycotically active formulation according to one of claims 1 to  
25 11 is applied to infected nails.
13. A method for the prophylaxis of fungal infections, in which a pharmaceutical, antimycotically active formulation according to one of claims 1 to 11 is applied to nails of subjects who are in danger of being affected by a nail fungal  
30 infection.